TITLE

Ariad's drug effective in certain leukemia treatment

PUB. DATE
May 2004
SOURCE
PharmaWatch: Cancer;May 2004, Vol. 3 Issue 5, p20
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
Reports that Ariad Pharmaceuticals Inc.'s lead product candidate, AP23464, has demonstrated its effectiveness in blocking the growth of leukemia cells that harbor mutations in the Abl protein that confer resistance to Gleevec, a primary treatment for chronic myelogenous leukemia (CML). Details of the study conducted by Harvard Medical School scientist George Q. Daley, et al, on the drug; Development of resistance to Gleevec in patients with CML; Findings from prior studies of AP23464.
ACCESSION #
13790346

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics